Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Return on Equity: 2014-2020

Historic Return on Equity for Larimar Therapeutics (LRMR) over the last 5 years, with Mar 2020 value amounting to -1.43%.

  • Larimar Therapeutics' Return on Equity fell 77.00% to -1.43% in Q1 2020 from the same period last year, while for Mar 2020 it was -1.43%, marking a year-over-year decrease of 77.00%. This contributed to the annual value of -0.98% for FY2019, which is 27.00% down from last year.
  • Per Larimar Therapeutics' latest filing, its Return on Equity stood at -1.43% for Q1 2020, which was up 6.55% from -1.54% recorded in Q4 2019.
  • Larimar Therapeutics' Return on Equity's 5-year high stood at -0.46% during Q1 2017, with a 5-year trough of -1.54% in Q4 2019.
  • In the last 3 years, Larimar Therapeutics' Return on Equity had a median value of -0.77% in 2018 and averaged -0.92%.
  • Data for Larimar Therapeutics' Return on Equity shows a peak YoY increase of 27bps (in 2019) and a maximum YoY decrease of 92bps (in 2019) over the last 5 years.
  • Over the past 5 years, Larimar Therapeutics' Return on Equity (Quarterly) stood at -0.46% in 2016, then fell by 16bps to -0.62% in 2017, then remained steady at -0.62% in 2018, then slumped by 92bps to -1.54% in 2019, then crashed by 77bps to -1.43% in 2020.
  • Its Return on Equity stands at -1.43% for Q1 2020, versus -1.54% for Q4 2019 and -0.80% for Q3 2019.